Jolanta Kosek

1.3k total citations
15 papers, 830 citations indexed

About

Jolanta Kosek is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Jolanta Kosek has authored 15 papers receiving a total of 830 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Hematology and 5 papers in Genetics. Recurrent topics in Jolanta Kosek's work include Protein Degradation and Inhibitors (7 papers), Multiple Myeloma Research and Treatments (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Jolanta Kosek is often cited by papers focused on Protein Degradation and Inhibitors (7 papers), Multiple Myeloma Research and Treatments (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Jolanta Kosek collaborates with scholars based in United States, Switzerland and Italy. Jolanta Kosek's co-authors include Peter Schäfer, Rajesh Chopra, Fatemeh Haghighi, Vundavalli V. Murty, Eldad A. Hod, Mitzi Morris, Éric Vilain, Benjamin Tycko, Alexandra Spadola and Nicole Schupf and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and Blood.

In The Last Decade

Jolanta Kosek

15 papers receiving 808 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jolanta Kosek United States	9	528	196	178	160	140	15	830
Clémence Carron France	18	665 1.3×	76 0.4×	192 1.1×	185 1.2×	183 1.3×	26	1.1k
Ana-Teresa Maia United Kingdom	15	703 1.3×	276 1.4×	298 1.7×	174 1.1×	76 0.5×	26	1.3k
Liubin Yang United States	13	917 1.7×	118 0.6×	513 2.9×	85 0.5×	180 1.3×	24	1.4k
Seppo Pakkala Finland	15	451 0.9×	220 1.1×	285 1.6×	110 0.7×	89 0.6×	33	757
Ricardo López‐Pérez Spain	18	614 1.2×	62 0.3×	448 2.5×	222 1.4×	131 0.9×	36	1.0k
Marina Lanciotti Italy	17	267 0.5×	215 1.1×	160 0.9×	129 0.8×	204 1.5×	51	733
Dijana Plaseska‐Karanfilska North Macedonia	14	311 0.6×	262 1.3×	103 0.6×	38 0.2×	48 0.3×	102	805
Juha Ollila Finland	11	416 0.8×	238 1.2×	51 0.3×	70 0.4×	226 1.6×	15	800
Evelio Perez‐Albuerne United States	10	380 0.7×	138 0.7×	126 0.7×	127 0.8×	92 0.7×	14	721
Maria De Angioletti Italy	17	219 0.4×	122 0.6×	223 1.3×	37 0.2×	135 1.0×	36	627

Countries citing papers authored by Jolanta Kosek

Since Specialization

Citations

This map shows the geographic impact of Jolanta Kosek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jolanta Kosek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jolanta Kosek more than expected).

Fields of papers citing papers by Jolanta Kosek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jolanta Kosek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jolanta Kosek. The network helps show where Jolanta Kosek may publish in the future.

Co-authorship network of co-authors of Jolanta Kosek

This figure shows the co-authorship network connecting the top 25 collaborators of Jolanta Kosek. A scholar is included among the top collaborators of Jolanta Kosek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jolanta Kosek. Jolanta Kosek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Schäfer, Peter, Alan Kivitz, Jianglin Ma, et al.. (2019). Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study. Rheumatology and Therapy. 7(1). 101–119. 45 indexed citations

Schäfer, Peter, Ying Ye, Lei Wu, et al.. (2018). Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus. Annals of the Rheumatic Diseases. 77(10). 1516–1523. 57 indexed citations

Nakayama, Yumi, Jolanta Kosek, Lori Capone, et al.. (2017). Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity. The Journal of Immunology. 199(7). 2388–2407. 39 indexed citations

Kosek, Jolanta, et al.. (2017). SAT0028 Aiolos overexpression in systemic lupus erythematosus b-cell subtypes and baff induced memory b-cell differentiation are reduced by cc-220 modulation of cereblon activity. Annals of the Rheumatic Diseases. 76. 778–778. 1 indexed citations

Schäfer, Peter, Francesca Truzzi, Anastasia Parton, et al.. (2016). Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. Cellular Signalling. 28(7). 753–763. 92 indexed citations

Wu, Lang, Jolanta Kosek, Ziwei Yang, et al.. (2015). OP0119 The CRL4 Cereblon E3 Ubiquitin Ligase Modulator CC-220 Induces Degradation of the Transcription Factors Aiolos and Ikaros: Immunomodulation in Healthy Volunteers and Relevance to Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases. 74. 113–113. 2 indexed citations

Hoffmann, Matthew, Claudia Kasserra, Peter Schäfer, et al.. (2012). Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemotherapy and Pharmacology. 71(2). 489–501. 98 indexed citations

Kosek, Jolanta, et al.. (2012). Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression. British Journal of Haematology. 160(4). 487–502. 123 indexed citations

Zhang, Linghua, Jolanta Kosek, Maria Wang, et al.. (2012). Lenalidomide Efficacy in Activated B-Cell-Like Subtype Diffuse Large B-Cell Lymphoma Is Dependent Upon IRF4 and Cereblon Expression. Blood. 120(21). 3287–3287. 5 indexed citations

10.

Gandhi, Anita K., Derek Mendy, Anastasia Parton, et al.. (2012). CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.. Blood. 120(21). 2963–2963. 8 indexed citations

11.

Kosek, Jolanta, et al.. (2010). Correlation of tumoricidal activity of lenalidomide against hematologic tumor cells with cyclin D1/D2 expression and effect on tumor-suppressor gene upregulation.. Journal of Clinical Oncology. 28(15_suppl). 8090–8090. 2 indexed citations

12.

Zhang, Linghua, Mary Adams, Jolanta Kosek, Peter Schäfer, & J. Blake Bartlett. (2009). Lenalidomide Inhibits Multiple Myeloma Cell Proliferation in Vitro Via Its Effect On Expression of Oncogenes and Tumor Suppressor Genes.. Blood. 114(22). 2855–2855. 2 indexed citations

13.

Spadola, Alexandra, Rui Yuan, Jolanta Kosek, et al.. (2008). Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nature Genetics. 40(7). 904–908. 328 indexed citations

14.

Han, Jin Hee, et al.. (1995). Modulation of apoptosis in human myeloid leukemic cells by GM-CSF.. PubMed. 23(3). 265–72. 24 indexed citations

15.

Caughey, George H., Stuart A. Rice, Jolanta Kosek, & Richard I. Mazze. (1979). Effect of phenytoin (DPH) treatment on methoxyflurane metabolism in rats.. Journal of Pharmacology and Experimental Therapeutics. 210(2). 180–185. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact